Select your Market
{{ userContent.title }}
Results of the third quarter of 2022
Forecast for fiscal 2022
Q3 2022 | Change (in %, | Organic growth (in %, | |
|---|---|---|---|
| Group net sales: | € 5.806 bn. | +16.8% | (organic: +7.1%) |
EBITDA pre: | € 1.810 bn. | +16.7% | (organic: +7.5%) |
Life Science: | € 2.681 bn. | +19.2% | (organic: +8.7%) |
Healthcare: | € 2.089 bn. | +19.9% | (organic: +8.7%) |
Electronics: | € 1.036 bn. | +10.6% | (organic: +0.4%) |
Despite the ongoing turbulence in our external operating environment, we’ve demonstrated our resilience and delivered strong organic growth in sales and EBITDA pre.”
Overview by CFO Marcus Kuhnert.
Detailed information about our business in the third quarter of 2022.
Downloads for the Media
Additional Downloads
Press Releases
Merck KGaA, Darmstadt, Germany, continued to grow in the third quarter of 2022 despite a challenging external operating environment. Group sales increased by 16.8% to € 5,806 million.
2022/11/10
